期刊文献+

注射用头孢派酮钠舒巴坦钠治疗外科急腹症临床疗效观察 被引量:1

The injectable cephalosporin send ketone sulbactam Clinical observation on the treatment of acute surgical abdomen
下载PDF
导出
摘要 目的比较头孢哌酮钠舒巴坦钠与头孢噻肟钠治疗外科急腹症中度感染的疗效性与安全性。方法外科急腹症病例109例,随机对照治疗,分为两组,其中头孢哌酮纳舒巴坦钠与头孢噻肟钠组分别为:55与54例,两组剂量均为4g/d、bid静脉滴注,疗程为5~10d。结果头孢哌酮钠舒巴坦钠与头孢噻肟钠的临床有效率为:90.91%和79.63%,细菌清除率分别为:88.24%和72.34%,头孢哌酮钠舒巴坦钠明显优于头孢噻肟钠,不良反应发生率分别为:5.45%和5.56%,无统计学显著差异。结论头孢哌酮钠舒巴坦钠治疗外科急腹症中度感染是一个安全有效的抗菌药物。 Objective To compare the efficacy and safety of surgical abdomen moderate infections with cefoperazone sulbactam and cefotaxime sodium. Methods 109 cases of cases of acute surgical abdomen, ran- domized controlled treatment were divided into two groups, which of sodium cefoperazone Nashubatan cefotaxime sodium, respectively: 55 and 54 cases, and the two groups are 4 g / d dose twice dailyintravenous infusion, treatment for 5 - 10 d. Results Cefoperazone sulbactam and cefotaxime sodium clinical effective rate: 90. 91% and 79.63%, bacterial clearance rates were as follows: 88.24% and 72. 34%, cefoperazone sulbac- tam significantly superior to cefotaxime sodium, adverse reactionrate: 5.45 % and 5.56%, respectively, and no statistically significant differences. Conclusion Cefoperazone sulbactam treatment surgical acute abdomen moderate infection is a safe and effective antimicrobial agents.
出处 《中国现代药物应用》 2012年第20期84-86,共3页 Chinese Journal of Modern Drug Application
关键词 头孢哌酮钠舒巴坦钠 头孢噻肟钠 急腹症 Cefoperazone sulbactam Cefotaxime sodium Acute abdomen
  • 相关文献

参考文献6

  • 1JoneRN, Barry AL, Thomsberry C, et al. The cofoperazone-salbac- tam combin ailon : invitro gualities including beta-lactamase stabili- ty, antimicrobial actirity, and interpretive criteria for disk diffusion tests. AJCP, 1985,84:496.
  • 2English AR, Retsema JA Girard AE, et al. Cp-451899, a beta- lactamase inhibitor that extends the antimicrobial spectrum of beta- laetams; inftial bacteriological characterization. Antimicrob Aents chemother, 1978,14:414.
  • 3Jones RN, Barrg AL. Cefoperazone: a review of its atimicrobial spectrum, f3-1actamase, stability, enzyme inhibition, and other in Vitro characteristis. Rev Infectis, 1983,5 (suppl) : 108.
  • 4Fass RJ, Gregort ww, D ' amaro RF, et 81. lnvitre activities of cefo- porazone and sulbactam singly and in combination against cefopera- zone-resistant members of the family enterobactaiacease and nonfer- menters. Antimicrob Agents Chemother, 1990,34:2256.
  • 5Jones Ran, Barrg AL. Cefoperazone: review of its. antimicrebial spectrum, Beta-lacta mase stability, enzy me inhibition, and other in vitro characterisbics. Rev in fect Dis, 1983,5 (supple) : 108.
  • 6Jones RN, Wilson Hw, Thomsberrgc, et al. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. Diagn micro- bial infect Dis ,1985,3167:369.

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部